Effects of Medications and Surgery on Intraocular Pressure Fluctuation

Survey of Ophthalmology

Volumn 53, Issue 6 SUPPL., 2008, Pages

  Sit, Arthur J ^a   Asrani, Sanjay ^b  

^a Mayo Clinic   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

circadian variations; duration of action; efficacy; fluctuations; glaucoma; intraocular pressure; medical therapy; prostaglandins; surgical therapy

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PLACEBO; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRABECULECTOMY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; FILTERING SURGERY; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE;

EID: 56449129227     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2008.08.009     Document Type: Article

References (58)

1. Asrani S., Zeimer R., Wilensky J., et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 9 (2000) 134-142
2. Bahler C.K., Howell K.G., Hann C.R., et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 145 (2008) 114-119
3. Bengtsson B., Leske M.C., Hyman L., et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 114 (2007) 205-209
4. Bron A.M., and Emmerich K.H. Latanoprost versus combined timolol and dorzolamide. Surv Ophthalmol 47 Suppl 1 (2002) S148-S154
5. Brown B., Burton P., Mann S., et al. Fluctuations in intra-ocular pressure with sleep: II. Time course of IOP decrease after waking from sleep. Ophthalmic Physiol Opt 8 (1988) 249-252
6. Brubaker R.F. Flow of aqueous humor in humans. [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci 32 (1991) 3145-3166
7. Brubaker R.F. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 45 Suppl 4 (2001) S347-S351
8. Brubaker R.F. Targeting outflow facility in glaucoma management. Surv Ophthalmol 48 Suppl 1 (2003) S17-S20
9. Caprioli J., and Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 115 (2008) 1123-1129 e3
10. Choi J., Kim K.H., Jeong J., et al. Circadian fluctuation of mean ocular perfusion pressure is a consistent risk factor for normal-tension glaucoma. Invest Ophthalmol Vis Sci 48 (2007) 104-111
11. Dailey R.A., Brubaker R.F., and Bourne W.M. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 93 (1982) 232-237
12. Drance S.M. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 64 (1960) 494-501
13. Dubiner H.B., Sircy M.D., Landry T., et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 26 (2004) 84-91
14. García-Feijoo J., Martínez-de-la-Casa J.M., Castillo A., et al. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22 (2006) 1689-1697
15. Graham S.L., and Drance S.M. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 43 Suppl 1 (1999) S10-S16
16. Hara T., Hara T., and Tsuru T. Increase of peak intraocular pressure during sleep in reproduced diurnal changes by posture. Arch Ophthalmol 124 (2006) 165-168
17. Henkind P., Leitman M., and Weitzman E. The diurnal curve in man: new observations. Invest Ophthalmol 12 (1973) 705-707
18. Hong S., Seong G.J., and Hong Y.J. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch Ophthalmol 125 (2007) 1010-1013
19. Ingram C.J., and Brubaker R.F. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol 128 (1999) 292-296
20. Kitazawa Y., and Horie T. Diurnal variation of intraocular pressure in primary open-angle glaucoma. Am J Ophthalmol 79 (1975) 557-566
21. Konstas A.G., Boboridis K., Tzetzi D., et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 123 (2005) 898-902
22. Konstas A.G., Katsimbris J.M., Lallos N., et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 112 (2005) 262-266
23. Konstas A.G., Lake S., Economou A.I., et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 124 (2006) 1553-1557
24. Konstas A.G., Maltezos A.C., Gandi S., et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 128 (1999) 15-20
25. Konstas A.G., Papapanos P., Tersis I., et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 110 (2003) 1357-1360
26. Konstas A.G., Topouzis F., Leliopoulou O., et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology 113 (2006) 761-765 e1
27. Kurtz S., and Shemesh G. The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure. J Ocul Pharmacol Ther 20 (2004) 321-327
28. Larsson L.I. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol 119 (2001) 492-495
29. Larsson L.I. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79 (2001) 567-571
30. Larsson L.I., Mishima H.K., Takamatsu M., et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 47 Suppl 1 (2002) S90-S96
31. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121 (2003) 48-56
32. Liu J.H., Kripke D.F., Hoffman R.E., et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci 39 (1998) 2707-2712
33. Liu J.H., Kripke D.F., Twa M.D., et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 40 (1999) 2912-2917
34. Liu J.H., Kripke D.F., and Weinreb R.N. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 138 (2004) 389-395
35. Liu J.H., Zhang X., Kripke D.F., et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 44 (2003) 1586-1590
36. Mansouri K., Orguel S., Mermoud A., et al. Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial. Br J Ophthalmol 92 (2008) 332-336
37. McCannel C.A., Heinrich S.R., and Brubaker R.F. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol 230 (1992) 518-520
38. Medeiros F.A., Pinheiro A., Moura F.C., et al. Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. J Ocul Pharmacol Ther 18 (2002) 489-498
39. Mosaed S., Liu J.H., and Weinreb R.N. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol 139 (2005) 320-324
40. Musch D.C., Gillespie B.W., Niziol L.M., et al. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 115 (2008) 927-933
41. Nouri-Mahdavi K., Hoffman D., Coleman A.L., et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111 (2004) 1627-1635
42. Orzalesi N., Rossetti I., Bottoli A., et al. Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 236 Suppl (2002) 55
43. Orzalesi N., Rossetti L., Bottoli A., et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113 (2006) 239-246
44. Orzalesi N., Rossetti L., Bottoli A., et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 121 (2003) 453-457
45. Orzalesi N., Rossetti L., Invernizzi T., et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41 (2000) 2566-2573
46. Quaranta L., Gandolfo F., Turano R., et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 47 (2006) 2917-2923
47. Schadlu R., Maus T.L., Nau C.B., et al. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol 116 (1998) 1441-1444
48. Schwartz G.F., Reardon G., and Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 137 (2004) S13-S16
49. Sit A.J., Nau C.B., McLaren J.W., et al. Circadian variation of aqueous dynamics in young healthy adults. Invest Ophthalmol Vis Sci 49 (2008) 1473-1479
50. Sit A.J., Weinreb R.N., Crowston J.G., et al. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 141 (2006) 1131-1133
51. Topper J.E., and Brubaker R.F. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 26 (1985) 1315-1319
52. Toris C.B., Gleason M.L., Camras C.B., et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 113 (1995) 1514-1517
53. Toris C.B., Zhan G., Fan S., et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 16 (2007) 189-195
54. Tsukamoto H., and Larsson L.I. Aqueous humor flow in normal human eyes treated with brimonidine and dorzolamide, alone and in combination. Arch Ophthalmol 122 (2004) 190-193
55. van der Valk R., Webers C.A., Schouten J.S., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 24 (2005) 1177-1185
56. Walters T.R., DuBiner H.B., Carpenter S.P., et al. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 49 Suppl 1 (2004) S26-S35
57. Werner E.B., Drance S.M., and Schulzer M. Trabeculectomy and the progression of glaucomatous visual field loss. Arch Ophthalmol 95 (1977) 1374-1377
58. Zeimer R.C., Wilensky J.T., and Gieser D.K. Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients. Ophthalmology 97 (1990) 547-550